Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Are Orphan Incentives Necessary For Development? Sponsors Aren't So Sure

Executive Summary

Drug sponsors tell US GAO that orphan incentives don't draw them to the space, and several stakeholders say high prices and scientific discovery are the reason for the sector's growth.
Advertisement

Related Content

US FDA May Create Rare Disease Expert Pool For Advisory Committee Reviews
Not A Loophole? BIO Concerned About Limiting Orphan Designations For Pediatric Subsets of Common Diseases
Rare Disease Supporters Suggest Permanent PRV Program, Even If It May Concern FDA
Drug Pricing Concerns May Hinder Rare Disease Lobbying Effort
Orphan Designations For Pediatric Subgroups Of Common Diseases To End
Disease 'Subsetting' Not Driving Jump In Orphan Designations, US FDA Says

Topics

Advertisement
UsernamePublicRestriction

Register

PS124355

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel